Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) traded up 6.7% during trading on Monday . The company traded as high as $13.10 and last traded at $13.02, with a volume of 53,295 shares changing hands. The stock had previously closed at $12.20.

Separately, Zacks Investment Research downgraded shares of Dipexium Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 3rd.

The company’s 50 day moving average price is $10.59 and its 200 day moving average price is $9.75. The stock’s market capitalization is $135.59 million.

Dipexium Pharmaceuticals (NASDAQ:DPRX) last released its earnings results on Thursday, August 4th. The company reported ($0.52) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.02. Analysts forecast that Dipexium Pharmaceuticals Inc. will post ($2.09) EPS for the current year.

Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.